JAMA Oncology
Original Investigation
October 1, 2019
Guillaume Assié, MD, PhD; Anne Jouinot, MD; Martin Fassnacht, MD, PhD; Rossella Libé, MD; Simon Garinet, PharmD; Louis Jacob, BS; Nadim Hamzaoui, MD; Mario Neou, MS; Julien Sakat, MD; Bruno de La Villéon, MD; Karine Perlemoine, BS; Bruno Ragazzon, PhD; Mathilde Sibony, MD; Frédérique Tissier, MD; Sébastien Gaujoux, MD, PhD; Bertrand Dousset, MD, PhD; Silviu Sbiera, MD, PhD; Cristina L. Ronchi, MD, PhD; Matthias Kroiss, MD, PhD; Esther Korpershoek, PhD; Ronald De Krijger, MD, PhD; Jens Waldmann, MD, PhD; Marcus Quinkler, MD, PhD; Magalie Haissaguerre, MD, PhD; Antoine Tabarin, MD, PhD; Olivier Chabre, MD, PhD; Michaela Luconi, MD, PhD; Massimo Mannelli, MD, PhD; Lionel Groussin, MD, PhD; Xavier Bertagna, MD, PhD; Eric Baudin, MD, PhD; Laurence Amar, MD, PhD; Joel Coste, MD, PhD; Felix Beuschlein, MD, PhD; Jérôme Bertherat, MD, PhD
free access
JAMA Oncol. 2019; 5(10):1440-1447. doi: 10.1001/jamaoncol.2019.1558
This biomarker analyss of patients with adrenocortical carcinoma compares the molecular classification for prognostic assessment of adrenocortical carcinoma with other known prognostic factors.
JAMA Dermatology
Brief Report
August 1, 2019
Guillaume Dachy, MD; Ronald R. de Krijger, MD, PhD; Sylvie Fraitag, MD; Ivan Théate, MD; Bénédicte Brichard, MD, PhD; Suma B. Hoffman, MD; Louis Libbrecht, MD, PhD; Florence A. Arts, PhD; Pascal Brouillard, PhD; Miikka Vikkula, MD, PhD; Nisha Limaye, PhD; Jean-Baptiste Demoulin, PhD
JAMA Dermatol. 2019; 155(8):946-950. doi: 10.1001/jamadermatol.2019.0114
This study assesses the frequency of PDGFRB mutations in sporadic solitary myofibroma and multifocal myofibromatosis found in samples from an international population of adults and children and describes their use as a diagnostic biomarker and a therapeutic target.